Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20497437rdf:typepubmed:Citationlld:pubmed
pubmed-article:20497437lifeskim:mentionsumls-concept:C0027662lld:lifeskim
pubmed-article:20497437lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:20497437lifeskim:mentionsumls-concept:C0009221lld:lifeskim
pubmed-article:20497437lifeskim:mentionsumls-concept:C2717879lld:lifeskim
pubmed-article:20497437lifeskim:mentionsumls-concept:C0694890lld:lifeskim
pubmed-article:20497437lifeskim:mentionsumls-concept:C0543431lld:lifeskim
pubmed-article:20497437lifeskim:mentionsumls-concept:C1516615lld:lifeskim
pubmed-article:20497437pubmed:issue1lld:pubmed
pubmed-article:20497437pubmed:dateCreated2010-12-14lld:pubmed
pubmed-article:20497437pubmed:abstractTextMultiple endocrine neoplasia type 2 (MEN 2) is a genetic syndrome caused by germline mutations in the RET proto-oncogene. These mutations cause changes in either the cysteine-rich extracellular domain or, less commonly, the non-cysteine intracellular domains of the RET protein. The genotype-phenotype correlations of classical cysteine RET mutations have been the subject of several comprehensive reviews. Less is known about the characteristics of the non-cysteine RET mutations. Studies of familial medullary thyroid cancer and MEN 2A kindreds carrying non-cysteine RET mutations have revealed a wide array of phenotypes, variable penetrance, and a diverse clinical course. The observed heterogeneity in disease expression has important diagnostic, therapeutic and prognostic implications. This review summarizes the genotypic and phenotypic characteristics of RET codon 804 mutation, a prototype for the less well-defined non-cysteine RET mutations associated with MEN 2.lld:pubmed
pubmed-article:20497437pubmed:languageenglld:pubmed
pubmed-article:20497437pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20497437pubmed:citationSubsetIMlld:pubmed
pubmed-article:20497437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20497437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20497437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20497437pubmed:statusMEDLINElld:pubmed
pubmed-article:20497437pubmed:monthJanlld:pubmed
pubmed-article:20497437pubmed:issn1399-0004lld:pubmed
pubmed-article:20497437pubmed:authorpubmed-author:MukherjeeSSlld:pubmed
pubmed-article:20497437pubmed:authorpubmed-author:ZakalikDDlld:pubmed
pubmed-article:20497437pubmed:copyrightInfo© 2010 John Wiley & Sons A/S.lld:pubmed
pubmed-article:20497437pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20497437pubmed:volume79lld:pubmed
pubmed-article:20497437pubmed:ownerNLMlld:pubmed
pubmed-article:20497437pubmed:authorsCompleteYlld:pubmed
pubmed-article:20497437pubmed:pagination1-16lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:meshHeadingpubmed-meshheading:20497437...lld:pubmed
pubmed-article:20497437pubmed:year2011lld:pubmed
pubmed-article:20497437pubmed:articleTitleRET codon 804 mutations in multiple endocrine neoplasia 2: genotype-phenotype correlations and implications in clinical management.lld:pubmed
pubmed-article:20497437pubmed:affiliationBeaumont Cancer Genetics Program, Beaumont Cancer Institute, William Beaumont Hospital, Royal Oak, MI 48073, USA. Sudipto.Mukherjee@beaumont.edulld:pubmed
pubmed-article:20497437pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20497437pubmed:publicationTypeReviewlld:pubmed
entrez-gene:5979entrezgene:pubmedpubmed-article:20497437lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20497437lld:entrezgene